1h Free Analyst Time
The Liver Disease Diagnostics Market size was estimated at USD 9.94 billion in 2023, USD 11.09 billion in 2024, and is expected to grow at a CAGR of 12.76% to reach USD 23.05 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The liver disease diagnostics market encompasses all technologies, products, and services dedicated to detecting and monitoring various liver conditions, including hepatitis, cirrhosis, liver cancer, and non-alcoholic fatty liver disease. The primary goal is to promote early detection, accurate staging, and effective management of liver-related diseases.
The rising prevalence of liver diseases, increased awareness and preventive approaches, and improvements in healthcare infrastructure across various regions have necessitated the adoption of liver disease diagnostics solutions. Additionally, supportive government initiatives and funding for liver disease research and management accentuate the need for liver disease diagnostics.
However, liver disease diagnostics faces challenges related to the high costs of advanced diagnostic tests, discrepancies in liver disease diagnostic standards, and limited accessibility in low-resource settings. Moreover, the lack of specific biomarkers for certain liver diseases and the risks associated with invasive diagnostic procedures can hinder growth. However, key players are exploring cutting-edge developments such as non-invasive imaging technologies and biomarker discovery to circumvent technical and safety complications. Furthermore, the increasing integration of AI and ML in diagnostics, which promises enhanced accuracy and predictive analytics, also opens up new avenues for growth. Personalized medicine and genomics are also gaining traction, offering the potential for tailored diagnostic and therapeutic approaches.
Regional Insights
The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement policies for various disease conditions, thereby fuelling the growth in liver disease diagnostics. Innovations in non-invasive imaging techniques and bio-marker identification are areas where significant investments and patent applications are seen. Initiatives such as the American Liver Foundation's efforts to improve liver health reflect the sector's proactive approach. The European Union displays diverse consumer behavior due to varying healthcare systems and economic capabilities across member countries.However, the adoption of the European Association for the Study of the Liver Clinical Practice Guidelines is a key factor in standardizing liver disease diagnostics. Increased R&D expenditure and multinational collaborations, such as those within the EU Horizon 2020 program, showcase the dynamic environment of innovation in the region. APAC region shows a burgeoning need for liver disease diagnostics due to the growing prevalence of liver-related disorders, growing awareness about liver health, and government initiatives to expand healthcare facilities to marginalized communities. The adoption of digital healthcare services and solutions is also gaining traction in the APAC region, which could create new avenues of growth for the industry.
Market Trends by Segment
- Diagnosis Technique: Ongoing advances to improve imaging modalities for liver disease diagnosis
- End-user: Expansion of hospitals across the world supported by government initiatives for developing robust healthcare infrastructure
Industry Insights
- Market Dynamics
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
- FPNV Positioning Matrix
- Market Share Analysis
- Strategy Analysis and Recommendations
Recent Developments
E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
E-Scopics, a provider of software-centric point-of-care ultrasound solutions, announced the commercial debut of its liver diagnostics technology, Hepatoscope, in the American market. The Hepatoscope offers an advanced ultraportable ultrasound system that can be utilized directly at the patient's bedside. This innovative device seamlessly incorporates the established technique of transient elastography to accurately measure liver stiffness measurement (LSM), along with advanced ultrasound imaging and quantification capabilities typically found in premium ultrasound equipment.Stone Diagnostics to Provide Fibronostics Liver Disease Test
Stone Diagnostics partnered with Fibronostics to broaden access to an innovative artificial intelligence-driven liver disease diagnostic tool known as Liverfast across the U.S. The Liverfast test leverages an AI algorithm and a panel of 10 blood-based biomarkers to accurately assess liver fibrosis, steatosis, and functional activity. This collaboration aims to enhance laboratory operations, catering to the growing demand for Liverfast and prioritizing the crucial needs of healthcare providers and their patients.Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease
Predictive Health Intelligence has unveiled the hepatoSIGHT tool, which is aimed at identifying individuals with previously undetected liver ailments through the analysis of historical blood test data. This innovative solution has shown promising results in pilot studies within the Somerset NHS Foundation Trust, demonstrating its capability to detect patients at risk for advanced liver disease at an early stage.Key Company Profiles
The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.This research report offers invaluable insights into various crucial aspects of the Liver Disease Diagnostics Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Liver Disease Diagnostics Market, by Diagnosis Technique
7. Liver Disease Diagnostics Market, by End-user
8. Americas Liver Disease Diagnostics Market
9. Asia-Pacific Liver Disease Diagnostics Market
10. Europe, Middle East & Africa Liver Disease Diagnostics Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Amgen Inc.
- Argon Medical Devices, Inc.
- Bayer AG
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- BioMérieux SA
- Boston Scientific Corporation
- Cook Medical Incorporated
- Epigenomics AG
- F. Hoffmann-La Roche Ltd.
- Fujifilm Holdings Corporation
- Hepatiq, Inc.
- Hologic, Inc.
- Horiba, Ltd.
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- Medtronic PLC
- Merck & Co., Inc.
- Perspectum Ltd.
- Quest Diagnostics Incorporated
- Randox Laboratories Ltd.
- Ri.Mos. Srl
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | May 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 11.09 Billion |
| Forecasted Market Value ( USD | $ 23.05 Billion |
| Compound Annual Growth Rate | 12.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
